Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Open access
Reiff, Sean D., Mantel, Rose, Smith, Lisa L., Greene, J.T., Muhowski, Elizabeth M., Fabian, Catherine A., Goettl, Virginia M., Tran, Minh, Harrington, Bonnie K., Rogers, Kerry A., Awan, Farrukh T., Maddocks, Kami, Andritsos, Leslie, Lehman, Amy M., Sampath, Deepa, Lapalombella, Rosa, Eathiraj, Sudharshan, Abbadessa, Giovanni, Schwartz, Brian, Johnson, Amy J., Byrd, John C., Woyach, Jennifer A. · 2018 · Cancer Discovery

Abstract

Targeted inhibition of Bruton tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL). Here, we describe preclinical investigations of ARQ 531, a potent, reversible inhibitor of BTK with additional activity against Src family kinases and kinases related to ERK signaling. We hypothesized that targeting additional kinases would improve global inhibition of signaling pathways, producing more robust responses. In vitro treatment of patient CLL cells with ARQ 531 decreases BTK-mediated functions including B-cell receptor (BCR) signaling, viability, migration, CD40 and CD86 expression, and NF-κB gene transcription. In vivo, ARQ 531 was found to increase survival over ibrutinib in a murine Eμ-TCL1 engraftment model of CLL and a murine Eμ-MYC/TCL1 engraftment model resembling Richter transformation. Additionally, ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLCγ2 mutants, which facilitate clinical resistance to ibrutinib. Significance: This study characterizes a rationally designed kinase inhibitor with efficacy in models recapitulating the most common mechanisms of acquired resistance to ibrutinib. Reversible BTK inhibition is a promising strategy to combat progressive CLL, and multikinase inhibition demonstrates superior efficacy to targeted ibrutinib therapy in the setting of Richter transformation. Cancer Discov; 8(10); 1300–15. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1195

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-1409

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 165

Metadata

Authors
Reiff, S. D., Mantel, R., Smith, L. L., Greene, J. T., Muhowski, E. M., Fabian, C. A., Goettl, V. M., Tran, M., Harrington, B. K., Rogers, K. A., Awan, F. T., Maddocks, K., Andritsos, L., Lehman, A. M., Sampath, D., Lapalombella, R., Eathiraj, S., Abbadessa, G., Schwartz, B., Johnson, A. J., Byrd, J. C., & Woyach, J. A.
Venue
Cancer Discovery
Published
2018-10-01
Volume
8
Issue
10
Pages
1300-1315
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2885382985
Cited by
165
References
9
FWCI
8.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-1409
The paper
Reiff, S. D., Mantel, R., Smith, L. L., Greene, J. T., Muhowski, E. M., Fabian, C. A., Goettl, V. M., Tran, M., Harrington, B. K., Rogers, K. A., Awan, F. T., Maddocks, K., Andritsos, L., Lehman, A. M., Sampath, D., Lapalombella, R., Eathiraj, S., Abbadessa, G., Schwartz, B., . . . Woyach, J. A. (2018). The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-1409

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.